Artificial intelligence is no longer a distant prospect in medicine—it is reshaping patient care, biomedical discovery, and healthcare efficiency. Leading medical institutions must prepare future leaders to harness AI in tackling the most pressing challenges in biomedicine. Harvard Medical School’s Department of Biomedical Informatics (DBMI) is rising to this challenge with the Artificial Intelligence in Medicine (AIM) PhD track—a program designed to cultivate physician-scientists and computational biologists who will redefine AI-driven healthcare.
Breyer Capital, a global leader in venture capital, has made a transformative commitment to this program, reinforcing its role as a top investor in healthcare AI. With a distinguished track record of backing computational biomedical companies at their earliest stages, Breyer Capital continues to shape medicine’s future by supporting exceptional talent and cutting-edge research. This investment will provide comprehensive training for students in the AIM PhD track over the next several years.
Read Full Story >